Nielsen Finn Stausholm, Sauer Jørgen, Bäcklund Johan, Voldborg Bjørn, Gregorius Klaus, Mouritsen Søren, Bratt Tomas
Pharmexa A/S, Kogle Allé 6, DK-2970 Hørsholm, Denmark.
J Biol Chem. 2004 Aug 6;279(32):33593-600. doi: 10.1074/jbc.M403072200. Epub 2004 Jun 1.
To create a human therapeutic vaccine able to circumvent self-tolerance against tumor necrosis factor (TNF) alpha, foreign T helper epitopes were inserted into human TNFalpha, with minimal effect on the native three-dimensional structure. TNFalpha variants were screened for solubility, structural stability, biological activity, and after immunization, for eliciting inhibitory antibodies. The longest and most flexible loop in TNFalpha, also designated loop 3, is the only region that is not involved in intra- or intermolecular interactions and therefore constitute an attractive insertion site. However, the extension of the flexible loop by epitope insertions destabilized the TNFalpha molecule. Therefore, two cysteines were introduced to form a stabilizing disulfide bond between loops 2 and 3. In a second design approach, three TNFalpha monomers were linked by two T cell epitopes and expressed as a single chain TNFalpha trimer. TNFalpha variants that were expressed as soluble proteins also had a conserved tertiary structure, as determined by circular dichroism. The biological activity of the TNFalpha variants was of the same magnitude as human TNFalpha in cellular assays. Introduction of three separate single-point mutations (D143N, A145R, or Y87S) diminished the cytotoxicity of the mutated variants 50-800-fold compared with native TNFalpha. Antisera from mice immunized with the different TNFalpha variants were able to cross-react with native human TNFalpha and to inhibit TNFalpha signaling via the TNF receptors in vitro, suggesting that the structural binding epitopes of native human TNFalpha and thus the native conformation were conserved in the constructed vaccine candidates.
为了制备一种能够规避针对肿瘤坏死因子(TNF)α的自身耐受性的人类治疗性疫苗,将外源T辅助表位插入人TNFα中,同时对天然三维结构的影响最小。对TNFα变体进行了溶解性、结构稳定性、生物活性筛选,并且在免疫后筛选了其诱导抑制性抗体的能力。TNFα中最长且最灵活的环,也称为环3,是唯一不参与分子内或分子间相互作用的区域,因此构成了一个有吸引力的插入位点。然而,通过表位插入扩展该灵活环会使TNFα分子不稳定。因此,引入了两个半胱氨酸以在环2和环3之间形成稳定的二硫键。在第二种设计方法中,三个TNFα单体通过两个T细胞表位连接并表达为单链TNFα三聚体。通过圆二色性测定,表达为可溶性蛋白的TNFα变体也具有保守的三级结构。在细胞试验中,TNFα变体的生物活性与人TNFα的生物活性相当。与天然TNFα相比,引入三个单独的单点突变(D143N、A145R或Y87S)使突变变体的细胞毒性降低了50至800倍。用不同TNFα变体免疫的小鼠的抗血清能够与天然人TNFα发生交叉反应,并在体外通过TNF受体抑制TNFα信号传导,这表明天然人TNFα的结构结合表位以及天然构象在构建的候选疫苗中得以保留。